Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
34
CCCC Quote, Financials, Valuation and Earnings
Last price:
$2.68
Seasonality move
:
-24.32%
Day range:
$2.57 - $2.76
52-week range:
$1.09 - $5.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.32x
P/B ratio:
1.68x
Volume:
2M
Avg. volume:
1.6M
1-year change:
-31.54%
Market cap:
$258.8M
Revenue:
$35.6M
EPS (TTM):
-$1.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$6.3M | -$0.39 | 7.69% | -25.47% | $11.86 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.34% | -4.29% | $178.76 |
|
FOLD
Amicus Therapeutics, Inc.
|
$164.6M | $0.11 | 20.07% | 224.54% | $15.90 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.47 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$2.67 | $11.86 | $258.8M | -- | $0.00 | 0% | 6.32x |
|
BIIB
Biogen, Inc.
|
$181.30 | $178.76 | $26.6B | 16.53x | $0.00 | 0% | 2.74x |
|
FOLD
Amicus Therapeutics, Inc.
|
$9.90 | $15.90 | $3.1B | -- | $0.00 | 0% | 5.07x |
|
GTBP
GT Biopharma, Inc.
|
$0.61 | $8.00 | $6.5M | -- | $0.00 | 0% | 59.35x |
|
IDYA
IDEAYA Biosciences, Inc.
|
$35.87 | $49.47 | $3.1B | -- | $0.00 | 0% | 14.77x |
|
PFE
Pfizer Inc.
|
$26.03 | $29.04 | $148B | 15.17x | $0.43 | 6.61% | 2.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
28.47% | 3.112 | 37.33% | 5.52x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics, Inc.
|
$9.2M | -$23.7M | -45.67% | -60.62% | -210.86% | -$31.6M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
C4 Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CCCC or BIIB?
Biogen, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 19%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About CCCC or BIIB?
C4 Therapeutics, Inc. has a consensus price target of $11.86, signalling upside risk potential of 344.09%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.4%. Given that C4 Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 BIIBBiogen, Inc.14 19 0 -
Is CCCC or BIIB More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock CCCC or BIIB?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or BIIB?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Biogen, Inc.'s net income of $466.5M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 6.32x versus 2.74x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M BIIBBiogen, Inc.2.74x 16.53x $2.5B $466.5M
-
Which has Higher Returns CCCC or FOLD?
Amicus Therapeutics, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 10.24%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About CCCC or FOLD?
C4 Therapeutics, Inc. has a consensus price target of $11.86, signalling upside risk potential of 344.09%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 60.61%. Given that C4 Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 FOLDAmicus Therapeutics, Inc.6 1 0 -
Is CCCC or FOLD More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock CCCC or FOLD?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or FOLD?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 6.32x versus 5.07x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M FOLDAmicus Therapeutics, Inc.5.07x -- $169.1M $17.3M
-
Which has Higher Returns CCCC or GTBP?
GT Biopharma, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of --. C4 Therapeutics, Inc.'s return on equity of -60.62% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About CCCC or GTBP?
C4 Therapeutics, Inc. has a consensus price target of $11.86, signalling upside risk potential of 344.09%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1212.77%. Given that GT Biopharma, Inc. has higher upside potential than C4 Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than C4 Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is CCCC or GTBP More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock CCCC or GTBP?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or GTBP?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 6.32x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns CCCC or IDYA?
IDEAYA Biosciences, Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 57.38%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat IDEAYA Biosciences, Inc.'s return on equity of -15.12%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B -
What do Analysts Say About CCCC or IDYA?
C4 Therapeutics, Inc. has a consensus price target of $11.86, signalling upside risk potential of 344.09%. On the other hand IDEAYA Biosciences, Inc. has an analysts' consensus of $49.47 which suggests that it could grow by 37.92%. Given that C4 Therapeutics, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe C4 Therapeutics, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 IDYAIDEAYA Biosciences, Inc.13 2 0 -
Is CCCC or IDYA More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison IDEAYA Biosciences, Inc. has a beta of 0.040, suggesting its less volatile than the S&P 500 by 96.023%.
-
Which is a Better Dividend Stock CCCC or IDYA?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEAYA Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. IDEAYA Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or IDYA?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than IDEAYA Biosciences, Inc. quarterly revenues of $207.8M. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than IDEAYA Biosciences, Inc.'s net income of $119.2M. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while IDEAYA Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 6.32x versus 14.77x for IDEAYA Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M IDYAIDEAYA Biosciences, Inc.14.77x -- $207.8M $119.2M
-
Which has Higher Returns CCCC or PFE?
Pfizer Inc. has a net margin of -286.43% compared to C4 Therapeutics, Inc.'s net margin of 21.32%. C4 Therapeutics, Inc.'s return on equity of -60.62% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital CCCCC4 Therapeutics, Inc.81.55% -$0.44 $215.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About CCCC or PFE?
C4 Therapeutics, Inc. has a consensus price target of $11.86, signalling upside risk potential of 344.09%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that C4 Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe C4 Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings CCCCC4 Therapeutics, Inc.7 0 0 PFEPfizer Inc.7 15 1 -
Is CCCC or PFE More Risky?
C4 Therapeutics, Inc. has a beta of 2.874, which suggesting that the stock is 187.406% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock CCCC or PFE?
C4 Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. C4 Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios CCCC or PFE?
C4 Therapeutics, Inc. quarterly revenues are $11.2M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. C4 Therapeutics, Inc.'s net income of -$32.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, C4 Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for C4 Therapeutics, Inc. is 6.32x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CCCCC4 Therapeutics, Inc.6.32x -- $11.2M -$32.2M PFEPfizer Inc.2.37x 15.17x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
